Sanofi-Aventis (SASY.PA) has reached an agreement in principle to acquire Genzyme Corp (GENZ.O) for about $19.2 billion in cash plus future payments based on the performance of an experimental Genzyme drug, according to two sources with knowledge of the talks. [ID:nN15191648] The news on Tuesday caps Sanofi's nearly nine-month pursuit of the U.S. biotech company as it seeks to shore up its revenue in the face of looming drug patent expirations. Here is an account of Sanofi's efforts to buy Genzyme. For complete coverage, see: [ID:nLDE70U1H1]
Source
